SAB BIOTHERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate
SAB BIOTHERAPEUTICS, INC. (SABS) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate of 100.00% for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate · last filed 2026-08-06
- SAB BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average volatility rate for the quarter ending 2026-06-30 was 100.00%, a 15.68% decline year-over-year.
- SAB BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average volatility rate for the quarter ending 2026-03-31 was 101.70%.
- SAB BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average volatility rate for the quarter ending 2025-09-30 was 124.40%, a 23.05% increase year-over-year.
- SAB BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average volatility rate for the quarter ending 2025-06-30 was 118.60%, a 31.19% increase year-over-year.
- SAB BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average volatility rate for fiscal 2025 was 109.10%, a 13.53% increase from fiscal 2024.
- SAB BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average volatility rate for fiscal 2024 was 96.10%, a 16.20% increase from fiscal 2023.
- SAB BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average volatility rate for fiscal 2023 was 82.70%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate 12 month |
|---|---|---|---|---|
| 2026-06-30 | 100.00% 10-Q · filed 2026-08-06 | 101.60% 10-Q · filed 2026-08-06 | ||
| 2026-03-31 | 101.70% 10-Q · filed 2026-05-12 | |||
| 2025-12-31 | 109.10% 10-K · filed 2026-03-09 | |||
| 2025-09-30 | 124.40% 10-Q · filed 2025-11-14 | 124.40% 10-Q · filed 2025-11-14 | ||
| 2025-06-30 | 118.60% 10-Q · filed 2026-08-06 | 118.60% 10-Q · filed 2026-08-06 | ||
| 2024-12-31 | 96.10% 10-K · filed 2026-03-09 | |||
| 2024-09-30 | 101.10% 10-Q · filed 2025-11-14 | 95.90% 10-Q · filed 2025-11-14 | ||
| 2024-06-30 | 90.40% 10-Q · filed 2025-08-07 | 89.90% 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | 89.90% 10-Q · filed 2025-05-09 | |||
| 2023-12-31 | 82.70% 10-K · filed 2025-03-31 | |||
| 2023-09-30 | 81.70% 10-Q · filed 2024-11-06 | |||
| 2023-06-30 | 80.90% 10-Q · filed 2024-08-08 | 81.70% 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | 81.90% 10-Q · filed 2024-05-20 | |||
| 2022-09-30 | 97.40% 10-Q · filed 2023-11-13 | 94.10% 10-Q · filed 2023-11-13 | ||
| 2022-06-30 | 85.40% 10-Q · filed 2022-08-10 | 79.00% 10-Q · filed 2022-08-10 | ||
| 2022-03-31 | 79.00% 10-Q · filed 2022-05-12 | |||
| 2021-09-30 | 98.10% 10-Q · filed 2022-11-14 | |||
| 2021-06-30 | 96.70% 10-Q · filed 2022-08-10 | 98.10% 10-Q · filed 2022-08-10 | ||
| 2021-03-31 | 104.30% 10-Q · filed 2022-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |